SEARCH

SEARCH BY CITATION

References

  • 1
    Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA et al. Can guideline-defined asthma control be achieved?: The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004;170: 836844.
  • 2
    Commonwealth Department of Health HaCS. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: APGS, 1992.
  • 3
    Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health, 1994.
  • 4
    Hjelmgren J, Berggren F, Andersson F. Health economic guidelines – similarities, differences and some implications. Value in Health 2001;4: 225250.
  • 5
    Pliskin JS, Shepard DS, Weinstein MC. Utility functions for life years and health status. Operations Research 1980;28: 206224.
  • 6
    Kind P. The EuroQoL instrument: an index of health-related quality of life. In: SpilkerB, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996: 191201.
  • 7
    Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005.
  • 8
    National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2004.
  • 9
    Towse A, Pritchard C, Devlin N. Cost-effectiveness thresholds. Office of Health Economics (OHE) Publication Briefing, 2002.
  • 10
    Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004;13: 437452.
  • 11
    Hill SR, Mitchell AS, Henry D. Problems with the interpretation of pharmacoeconomic anlayses. A review of submission to the Australian Pharmaceutical Benefits Scheme. JAMA 2000;283: 21162121.
  • 12
    Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132: 780787.